Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET

Asthma worsening and symptom control are clinically important health outcomes in patients with severe eosinophilic asthma. This analysis of COMET evaluated whether stopping versus continuing long-term mepolizumab therapy impacted these outcomes. Patients with severe eosinophilic asthma with ≥3 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mark C., Bel, Elisabeth H., Kornmann, Oliver, Moore, Wendy C., Kaneko, Norihiro, Smith, Steven G., Martin, Neil, Price, Robert G., Yancey, Steven W., Humbert, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752942/
https://www.ncbi.nlm.nih.gov/pubmed/35036420
http://dx.doi.org/10.1183/23120541.00419-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752942/
https://www.ncbi.nlm.nih.gov/pubmed/35036420
http://dx.doi.org/10.1183/23120541.00419-2021

Ejemplares similares